Trademark: 97420511
Word
SCRIBE THERAPEUTICS
Status
Pending
Status Code
730
Status Date
Sunday, December 10, 2023
Serial Number
97420511
Mark Type
4000
Filing Date
Friday, May 20, 2022
Published for Opposition
Tuesday, April 25, 2023

Trademark Owner History
Scribe Therapeutics Inc. - Owner At Publication

Classifications
5 Pharmaceutical and biological preparations based on genetic engineering and gene therapy for use in diagnosis, prevention, and treatment of diseases in human therapeutics, namely, diseases caused by genetic mutations and diseases and disorders for which gene modification would ameliorate or cure; Gene therapy products, namely, biological preparations based on engineered cells for medical use for the treatment of diseases caused by genetic mutations and of diseases and disorders for which gene modification would ameliorate or cure related to immuno-oncology, degenerative disorders, traumatic injury, enzyme replacement therapy, and immunology; Pharmaceutical and biological preparations based on gene, genome, and cellular editing, modulation, and modification for use in human therapeutics, namely, for the diagnosis, prevention, and treatment of diseases caused by genetic mutations and of diseases and disorders for which gene modification would ameliorate or cure; Pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders, namely, neurological disorders, Huntington's disease, amyotrophic lateral sclerosis (ALS), front temporal dementia, Alzheimer's, Parkinson's, ataxia, autism, epilepsy, and pain, and also for the prevention and treatment of cardiovascular, peripheral nervous system, endocrine, gastrointestinal, renal, genetic immunological, hepatic, infectious, inflammatory, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, respiratory, urogenital, urological, and hematologic diseases and disorders, and cancer
44 Molecular diagnostic services in the nature of genetic testing for medical purposes; Medical diagnostic testing services in the field of human disease and human medical conditions
42 Scientific and medical research in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic transcriptional regulation, genetic transcriptional modulation, genetic diseases, gene therapy and cell therapy, and genetic engineering research and development of pharmaceuticals, biological preparations, and therapeutic products and services; Design and development of engineered cells for use in scientific research and in drug discovery and development; Providing medical and scientific research information in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic transcriptional regulation, genetic transcriptional modulation, genetic diseases, gene therapy and cell therapy, and genetic engineering; Molecular diagnostic services in the nature of genetic testing for medical research purposes
"THERAPEUTICS"

Trademark Events
Dec 12, 2023
Notice Of Approval Of Extension Request E-Mailed
Dec 10, 2023
Sou Extension 1 Granted
Dec 10, 2023
Sou Extension 1 Filed
Dec 10, 2023
Sou Teas Extension Received
Jun 20, 2023
Noa E-Mailed - Sou Required From Applicant
Apr 25, 2023
Official Gazette Publication Confirmation E-Mailed
Apr 25, 2023
Published For Opposition
Apr 5, 2023
Notification Of Notice Of Publication E-Mailed
Mar 16, 2023
Approved For Pub - Principal Register
Mar 16, 2023
Examiner's Amendment Entered
Mar 16, 2023
Notification Of Examiners Amendment E-Mailed
Mar 16, 2023
Examiners Amendment E-Mailed
Mar 16, 2023
Examiners Amendment -Written
Mar 9, 2023
Assigned To Examiner
May 25, 2022
New Application Office Supplied Data Entered
May 24, 2022
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24